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then, several studies have described the prevalence of an CD56negCD16pos NK cell subset in viral non-
controllers as the basis for their NK cell dysfunction. However, the mechanistic basis for their cytotoxic
impairment is unclear. Recently, using a strict flow cytometry gating strategy to exclude monocytes,
we reported an accumulation of CD56negCD16pos NK cells in Plasmodium falciparum malaria-exposed
children and pediatric cancer patients diagnosed with endemic Burkitt lymphoma (eBL). Here, we use
live-sorted cells, histological staining, bulk RNA-sequencing and flow cytometry to confirm that this
CD56negCD16pos NK cell subset has the same morphological features as the other NK cell subsets and a
similar transcriptional profile compared to CD56dimCD16pos NK cells with only 120 genes differentially
expressed (fold change of 1.5, p < 0.01 and FDR<0.05) out of 9235 transcripts. CD56negCD16pos NK
cells have a distinct profile with significantly higher expression of MPEG1 (perforin 2), FCGR3B (CD16b),
FCGR2A, and FCGR2B (CD32A and B) as well as CD6, CD84, HLA-DR, LILRB1/2, and PDCD1
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KLRF1 (NKp80) and NCR1 (NKp46), and inhibitory HAVCR2 (TIM-3) are significantly down-regulated
compared to CD56dimCD16pos NK cells. Together, these data confirm that CD56negCD16pos cells
are legitimate NK cells, yet their transcriptional and protein expression profiles suggest their cytotoxic
potential is mediated by pathways reliant on antibodies such as antibody-dependent cell cytotoxicity
(ADCC), antibody-dependent respiratory burst (ADRB), and enhanced by complement receptor 3 (CR3)
and FAS/FASL interaction. Our findings support the premise that chronic diseases induce NK cell
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Natural Killer (NK) cells play an essential role in antiviral and anti-tumoral immune
responses. In peripheral blood, NK cells are commonly classified into two major
subsets: CD56brightCD16neg and CD56dimCD16pos despite the characterization of a
CD56negCD16pos subset 25 years ago. Since then, several studies have described
the prevalence of an CD56negCD16pos NK cell subset in viral non-controllers as the
basis for their NK cell dysfunction. However, the mechanistic basis for their cytotoxic
impairment is unclear. Recently, using a strict flow cytometry gating strategy to exclude
monocytes, we reported an accumulation of CD56negCD16pos NK cells in Plasmodium
falciparum malaria-exposed children and pediatric cancer patients diagnosed with
endemic Burkitt lymphoma (eBL). Here, we use live-sorted cells, histological staining,
bulk RNA-sequencing and flow cytometry to confirm that this CD56negCD16pos NK
cell subset has the same morphological features as the other NK cell subsets and
a similar transcriptional profile compared to CD56dimCD16pos NK cells with only 120
genes differentially expressed (fold change of 1.5, p < 0.01 and FDR<0.05) out of
9235 transcripts. CD56negCD16pos NK cells have a distinct profile with significantly
higher expression of MPEG1 (perforin 2), FCGR3B (CD16b), FCGR2A, and FCGR2B
(CD32A and B) as well as CD6, CD84, HLA-DR, LILRB1/2, and PDCD1 (PD-1), whereas
Interleukin 18 (IL18) receptor genes (IL18RAP and IL18R1), cytotoxic genes such as
KLRF1 (NKp80) and NCR1 (NKp46), and inhibitory HAVCR2 (TIM-3) are significantly
down-regulated compared to CD56dimCD16pos NK cells. Together, these data confirm
that CD56negCD16pos cells are legitimate NK cells, yet their transcriptional and protein
expression profiles suggest their cytotoxic potential is mediated by pathways reliant on
antibodies such as antibody-dependent cell cytotoxicity (ADCC), antibody-dependent
respiratory burst (ADRB), and enhanced by complement receptor 3 (CR3) and FAS/FASL
interaction. Our findings support the premise that chronic diseases induce NK cell
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modifications that circumvent proinflammatory mediators involved in direct cytotoxicity.
Therefore, individuals with such altered NK cell profiles may respond differently to
NK-mediated immunotherapies, infections or vaccines depending on which cytotoxic
mechanisms are being engaged.
Keywords: natural killer cells, CD56negCD16pos subset, endemic Burkitt lymphoma, malaria, epstein-barr virus,
transcription profile
INTRODUCTION
Natural Killer (NK) cells are crucial mediators of innate
immune responses against virally infected and malignant cells
(Herberman et al., 1975; Kiessling et al., 1975; Trinchieri
and Santoli, 1978). NK cell function depends on a balance
between activation and inhibition signals triggered by multiple
surface receptors engaged during their surveillance of host
cells (Long et al., 2013). NK cells were originally defined as
CD3negCD56pos cells and represent 10 to 15% of lymphocytes
in peripheral blood (Robertson and Ritz, 1990). CD56 is a
Neural Cell Adhesion Molecule 1 (NCAM-1) involved in cell-
to-cell and cell-to-matrix interactions (Lanier et al., 1991) and
its expression varies with NK cell maturation. Of the peripheral
NK cells, ∼10% are CD56bright NK cells which are essential
for pro-inflammatory cytokine production (Cooper et al., 2001)
particularly when they also express CD62L, an adhesion/homing
molecule (Cichocki et al., 2016) and are less cytotoxic (Jacobs
et al., 2001); whereas CD56dim NK cells comprise ∼90% of
NK cells in healthy adults and have low cytokine production
but high cytotoxic capacity (Cooper et al., 2001; Jacobs et al.,
2001). CD56dim NK cells are polyfunctional and play either
an immunoregulatory role as canonical CD56dim NK cells
characterized as CD62LnegCD57pos Eomesoderminpos (Eomes)
Promyelocytic Leukemia Zinc Fingerpos (PLZF) (Cichocki et al.,
2016) or are considered adaptive NK cells which do not express
PLZF or FcRγ (also referred to as an Immunoreceptor Tyrosine-
based Activation Motif (ITAM)-bearing transmembrane adapter
protein). Adaptive NK cells are involved in immunosurveillance
with induction of cytotoxic granules (perforin and granzymes)
upon engagement with CD16, NKG2C or activating Killer
Immunoglobulin-like Receptor (KIR) (Hwang et al., 2012;
Schlums et al., 2015; Tesi et al., 2016). Recently, adaptive
CD56dim NK cells were associated with protection from
Plasmodium falciparum (Pf ) malaria (Hart et al., 2019). Pf-
exposed individual had a higher frequency of FcRγneg adaptive
CD56dim NK cells and displayed increased antibody-dependent
cellular cytotoxicity (ADCC) against Pf-infected red blood cells
(Hart et al., 2019).
CD56negCD16pos NK cells were discovered 25 years ago in
Human Immunodeficiency Virus (HIV) patients (Hu et al.,
1995) and has been shown to expand during other chronic
infections, such as Hepatitis C Virus (HCV), especially
those who failed treatment (Mavilio et al., 2003, 2005;
Gonzalez et al., 2009; Prada et al., 2013) and more recently
in human Cytomegalovirus (HCMV) and Epstein-Barr virus
(EBV) co-infected elderly individuals (>60 years of age)
(Müller-Durovic et al., 2019). Compared to CD56pos NK cells,
CD56neg NK cells have been portrayed as “dysfunctional”
because of lower expression of cytotoxic receptors such as
NKp46 and NKp30, low cytokine production as well as
reduction of natural cytotoxicity (Mavilio et al., 2005; Müller-
Durovic et al., 2019). More recently, we reported a dramatic
expansion of CD56negCD16pos NK cells in African children
chronically/repeatedly infected with Plasmodium falciparum
malaria and in those who were diagnosed with endemic
Burkitt lymphoma (eBL) (Forconi et al., 2018). Proteomic
analyses showed similarities between CD56dimCD16pos and
CD56negCD16pos NK cells (Voigt et al., 2018) thus supporting the
classification of this subset as NK cells. Since CD56negCD16pos
NK cells are extremely low in American/European healthy
adults (Supplemental Figure 1), most studies have focused
on characterizing the function and therapeutic potential
of CD56bright and CD56dim NK cell subsets. However, it
appears that healthy adults from western Kenya also have a
significant proportion of CD56negCD16pos NK cells, similar
to children chronically/repeatedly infected with Pf-malaria
(Supplemental Figure 1). Besides the emerging evidence
associating this NK cell subset with chronic infections, the
development and function of CD56negCD16pos NK cells have
only begun to be explored.
Endemic BL is an Epstein-Barr virus (EBV) associated,
aggressive pediatric cancer that occurs in regions of equatorial
Africa with high P. falciparum transmission, i.e., holoendemic
malaria (Burkitt, 1962). EBV is a herpesvirus which has evolved
to evade immune clearance in order to establish a life-long,
asymptomatic infection within immunocompetent individuals
(Schmiedel andMandelboim, 2017). Children residing inmalaria
holoendemic areas, where eBL incidence is high, are usually
infected by EBV before 2 years of age (Piriou et al., 2012). At
the same time these children are repeatedly infected with P.
falciparum which in turn induces episodes of viral reactivation
resulting in higher EBV loads (Moormann et al., 2005; Piriou
et al., 2012; Reynaldi et al., 2015). P. falciparum malaria is
postulated to diminish EBV-specific immune surveillance as a
component of eBL etiology, a cancer common in children aged
5–9 years (Moss et al., 1983; Whittle et al., 1984; Moormann
et al., 2007, 2009; Njie et al., 2009; Snider et al., 2012;
Chattopadhyay et al., 2013; Parsons et al., 2016). NK cells
have been independently shown to help control both of these
infections, killing EBV-infected B cells during adolescent acute
infectious mononucleosis (AIM) (Azzi et al., 2014) and malaria-
infected red blood cells (Horowitz et al., 2010; Wolf et al., 2017).
However, little is known about NK cell function during EBV
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and malaria co-infections and their role in protection against
eBL pathogenesis.
In order to further clarify similarities and differences between
CD56dimCD16pos and CD56negCD16pos NK cells we performed
histology staining, bulk RNA sequencing and protein expression
profile validation by flow cytometry using fluorescence-activated
cell sorting (FACS) of NK subsets of peripheral blood
mononuclear cells (PBMCs) isolated from children who had life-
long exposure to P. falciparum infections and were diagnosed
with eBL.
METHODS
Study Population and Ethical Approvals
Ethical approval was obtained from the Scientific and Ethics
Review Unit (SERU) at the Kenya Medical Research Institute
(KEMRI) and the Institutional Review Board at the University
of Massachusetts Medical School, Worcester, USA. Written
informed consent was obtained from adults and from parents
of minor study participants. Healthy children and adults
were recruited at a rural health center in Kenya. Inclusion
criteria for children were EBV sero-positivity, HIV-negative
and born to HIV-negative mothers. Inclusion criteria for
Kenyan and American adults was HIV-negative status. Children
with suspected eBL were enrolled at Jaramogi Oginga Odinga
Teaching and Referral Hospital (JOOTRH) in Kisumu, Kenya.
Two independent pathologists confirmed diagnosis by cyto-
pathology and May-Grunwald Giemsa staining. Tumor samples
were further characterized by transcriptome and mutational
profiling to confirm eBL diagnosis (Kaymaz et al., 2017). This
cancer is more prevalent in male compared to female children,
with a peak-age incidence ranging from 5 to 9 years old (Buckle
et al., 2016), and at the time of this study, we only had sufficient
samples from male eBL children. Therefore, baseline peripheral
blood samples were used from 8 male eBL children before
induction of chemotherapy. However, we have previously shown
that bothmale and female eBL patients have significantly elevated
frequencies of CD56negCD16pos NK cells (Forconi et al., 2018).
ddPCR to Quantify EBV Load
For each patient, 500 µl of blood was collected in an EDTA
microtainer tube. After 5min of centrifugation, 200 µl of plasma
was separated from the blood cell pellet and replaced by an
equivalent amount of 1X PBS, pH 7.4. Using the whole blood
DNA extraction kit from Qiagen, DNA was isolated from the
PBS resuspended blood cell pellet and total DNA concentration
was measured by NanoDrop (Thermo Fisher Scientific). We
used digital droplet PCR (ddPCR) to determine EBV load in
each sample by amplifying EBV BALF5 and human β-actin
gene, using primers and probes shown in Table 1. The duplex
ddPCR reactions were prepared in a total volume of 20 µl
which contained 10 µl of ddPCR Supermix for probes (No
UTP) (Bio-Rad Laboratories), and 2 sets of each primer and
probe combination (0.9µM of primers and 0.25µM of probes).
The BioRad Automated Droplet Generator (AutoDG) (Bio-Rad
Laboratories) was used to ensure consistent droplet generation.
After the ddPCR reaction, the number of positive and negative





EBV-BALF5 Probe FAM -TGTACACGCACGAGAAATGCGCCT-BHQ-1
Human β-actin FP GCTCATGGCAAGAAAGTGCTC
Human β-actin RP GCAAAGGTGCCCTTGAGGT
Human β-actin Probe HEX-AGTGATGGCCTGGCTCACCTGGAC-BHQ
FP, Forward primer; RP, Reverse primer.
droplets were counted by the Bio-Rad QX200TM Droplet reader
and EBV viral loads quantified as copies/ng human DNA.
Multiplex Suspension Bead-Based
Serology Assay
To measure IgG antibody levels in the plasma fraction, we
used a Luminex bead-based suspension assay as previously
published (Cham et al., 2009; Forconi et al., 2018). In brief,
antibodies to Viral Capsid Antigen (VCA) and Epstein-Barr
nuclear antigen 1 (EBNA1) (gift from Jaap Middeldorp, Cyto-
Barr) were used to determine EBV seropositivity (Middeldorp
and Herbrink, 1988; van Grunsven et al., 1994). Previous P.
falciparum exposure was determined using recombinant proteins
to blood stage malaria antigens: apical membrane antigen 1
(AMA1) and merozoite surface protein (MSP1) (gifts from
Sheetji Dutta, Evelina Angov, and Elke Bergmann from the
Walter Reed Army Institute of Research). Briefly, 200 µg of
each antigen or bovine serum albumin (BSA) (Sigma-Aldrich)
were coupled to carboxylated beads microspheres (BioRad)
and then incubated with plasma samples from our study
participants, followed by incubation with biotinylated anti-
human IgG diluted 1:1000 and streptavidin (BD Pharmingen)
diluted 1:1000 following manufacturer’s instructions. Antigen-
specific fluorescence values were quantified on a BioPlex 200
multi-analyte analyzer with subtraction of fluorescence values
obtained with BSA-conjugated beads for each patient. Results are
reported as median fluorescence intensity (MFI) after acquisition
of a minimum of 50 beads per antigen.
Fluorescence-Activated Cell Sorting
(FACS) of NK Subsets
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Paque density gradient centrifugation and cryopreserved
until use (viability > 97%). PBMCs were thawed at 37◦C
in complete media composed of RPMI, 10% heat-inactivated
Fetal Bovine Serum (MilliporeSigma), 2mM L-glutamine, 1X
Penicillin/Streptomycin and 10mMHEPES (Invitrogen). NK cell
subsets were then isolated using a 16-color BD FACS 2-ARIA
II cell sorter at the UMASS Flow Cytometry Core. The gating
strategy (Figure 1) used the following antibody/fluorochrome
combinations identified by the Resource Identification Portal
number RRID to isolate NK subsets: CD16-BV510 (RRID:
AB_2562085) and CD56-PECy7 (RRID: AB_399970) with the
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3 April 2020 | Volume 10 | Article 162
Forconi et al. New Hope for CD56negCD16pos NK Cells
FIGURE 1 | Gating strategy for FACS and HandE staining. PMBCs were gated on (A) lymphocytes size determined by SSC-A vs. FSC-A cytoplots, then (B) live, and
(C) single cells were selected. (D) A Dump channel was used to eliminate CD3+, CD14+, and CD19+ cells. These cells were stained purple using hematoxylin and
eosin (HandE), as shown in photo 1. Then (D) CD3−CD14−CD19− cells were (E) sorted based on CD56 vs. CD16 expression and the three isolated NK cell subsets
were stained with HandE: photo 2 CD56brightCD16neg, photo 3 CD56dimCD16pos, and photo 4 CD56negCD16pos.
exclusion of dead cells by 7’AAD (BD Pharmingen, Cat#559925)
and dump channel for cells expressing either CD3-BV421
(RRID: AB_10962690), CD14-BV421 (RRID: AB_2563296), or
CD19-BV421 (RRID: AB_11142678). In order to compare cell
morphology between CD56dimCD16pos and CD56negCD16pos
NK cell subsets, we also collected the CD56brightCD16neg NK cells
and CD3+CD14+CD19+ cells.
Morphology by Light Microscopy
To examine morphology, live-sorted cells from each subset
were cytospun on a slide and stained with hematoxylin and
eosin (H&E) following Hema 3TM Stat Pack kit instructions
(Fisherbrand Cat#122-911). Hematoxylin stains the nucleus deep
blue-violet whereas eosin stains the elastin/collagen/reticular
fibers of the cell pink. Slides were imaged on Nikon microscope
Eclipse E400 with ocular lens 10x and 100x objectives using the
DS-Qi1MC and Digital Sight DS-U3 (Nikon) camera system and
NIS-Element BR version 4.20 software. Images were analyzed by
a clinical pathologist and transfusion specialist at UMass Medical
School to determine cell types.
RNA Sequencing
Live-FACS sorted NK cell subsets (CD56dimCD16pos and
CD56negCD16pos) were immediately collected in 4◦C 2× Buffer
TCL with (2%) β-mercaptoethanol (Qiagen). Total RNA was
isolated and strand-specific ribosomal RNA-depleted sequencing
libraries were generated using the standard protocol of SMARTer
Stranded Total RNA-Seqv2 Pico input kit (Takara Bio). Given
the small quantity of total RNA that was obtained from the
∼5,000 NK cells sorted for each subset, the depletion of abundant
rRNA was performed after cDNA synthesis using probes specific
to mammalian rRNA. Sequencing libraries were purified using
XP Ampure magnetic beads (Beckman Coulter Inc.) after each
reaction step. Final libraries were amplified using SeqAmp DNA
polymerase, and qualities and concentrations were measured
with a Bioanalyzer Agilent High sensitivity DNA kit. Samples
were sequenced on an Illumina HiSeq 4000 (Illumina, Inc.),
obtaining depths of 10–20 million paired-end 50 bp reads for
each NK cell subset sequenced. Sequencing files were deposited
in the NCBI’s database of Genotypes and Phenotypes (dbGaP)
with accession number phs001282.v2.p1.
Differential Gene Expression Analysis
Differential gene expression was performed using standard
methods. Sequence reads were first checked for quality using
FastQC (Andrews, 2014) and sorted by sample based on the
unique sample indexes identified by Novobarcode (Novocraft
Technologies). Residual Illumina 3’-end adaptor sequences and
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template switching oligos introduced during the cDNA synthesis
were trimmed using Cutadapt (Martin, 2011). Paired reads were
then aligned to a transcriptome index built by RNA-Seq by
expectation-maximization (RSEM) (Li and Dewey, 2011) using
Gencode annotation version 19 for protein coding transcripts
and hg19 genomic sequence. RSEM calculated strand-specific
expected read counts for each gene and gene expression count
matrices for each NK cell subset were generated for downstream
statistical analyses that were performed with R software (https://
www.R-project.org/) (version 3.5.3).
Differential gene expression analysis between NK cell subsets
(CD56dimCD16pos and CD56negCD16pos) was performed using
R package edgeR (Robinson et al., 2010) which implements
a Trimmed mean of M-values (TMM) normalization and a
negative binomial approach (Robinson and Oshlack, 2010).
We removed from the analysis all genes for which all counts
per million (CPM) values were lower than 5 cpm. To
control multiple testing, we applied the Benjamini-Hochberg
procedure (BH) with threshold for statistical significance
set at an adjusted p-value < 0.01 and false discovery
rate (FDR) < 0.05.
Validation by Flow Cytometry
PBMCs from 3 eBL children (2 of them were also used for
RNA-sequencing) and 3 healthy Kenyan children were thawed
and FACS live-sorted, as described above. In addition, we
included the following antibodies: CD62L-PerCP5.5 (RRID:
AB_2239105), DNAM1-BV711 (RRID: AB_2738956), TIM3-
BV650 (RRID: AB_2565829), PD-1-APC-Fire750 (RRID:
AB_2616721) and granzyme B-APC (RRID: AB_1500190);
CD32-PerCP5.5 (RRID: AB_2616924) and IL18Ra-APC
(RRID: AB_2800828). Data was acquired on a 19-color BD
LSRII at the UMASS FACS Core and analyzed using FlowJo
v10.6.0, R v3.5.1 and Prism v8.3.0. Non-parametric two-tailed
paired Wilcoxon t-test was used and a p-value <0.05 was
considered significant.
gProfiler
The genes identified to be significantly differentially expressed
(p-value < 0.01 and FDR < 0.05) between the NK cell
subsets were further analyzed using the gProfiler software
(https://biit.cs.ut.ee/gprofiler) (Raudvere et al., 2019) to explore
the potential functional consequences and associated pathways.
gProfiler was run using g:GOSt ordered query with Bonferroni
correction and a threshold of 0.01 equating to a p-unadjusted
< 10.E-16.
RESULTS
Characterization of the Samples
Initial samples at diagnosis prior to chemotherapy from 8 eBL
children were used for this study with a median age of 9.5
years (Table 2). Serology for the two pathogens associated with
eBL was assessed and all children were seropositive for both
EBV and P. falciparum. Survival outcomes varied with five eBL
children (62%) being long-term (>2 year) survivors and three
(38%) in-hospital deaths. Half of the children had low EBV
TABLE 2 | Patients characteristics.
eBL (n = 8)
Age†: 9.5 [6.5–11.75]
Sex: (Male) 8
Hemoglobin (g/dl)† 10.80 [9.75–11.55]
ALC: (103 lymphocytes per µl)† 346.8 [214.1–418.4]









Low EBV viral load: (eBL n = 4)†
EBV copies/ng human DNA
0.5 [0.11–0.7]
High EBV viral load: (eBL n = 4)†





% CD56dim within NK cells†: 56.6 [34.55–67.1]
% CD56neg within NK cells†: 30.30 [24.23–57.1]
†
Median [25–75% interquartile].
loads (median 0.5 EBV copies/ng of human DNA) and half had
high EBV loads (median 23.3 copies/ng of human DNA). No
child in our study had lymphopenia with a median absolute
lymphocyte count (ALC) of 3.5 × 105 lymphocytes per µl blood
(Shapiro et al., 1998). Finally, the percentage of each NK subset
was assessed within the total NK cell population. Consistent
with our previous study (Forconi et al., 2018), eBL children
had elevated CD56neg CD16pos NK cell subset, with a median
of 30.3%.
Morphology of CD56negCD16pos Cells
Similar to Other NK Subsets
After live-sorting, an aliquot of each cell subset was fixed
and stained by H&E in order to assess their morphology
(Figure 1). All three NK cell subsets CD56brightCD16neg
(Figure 1, photo 2), CD56dimCD16pos (Figure 1, photo
3) and CD56negCD16pos (Figure 1, photo 4) had similar
morphology by microscopy, round in shape, ∼10µm in size
and with a prominent nucleus typical of lymphocyte histology.
Importantly, these cells differed morphologically compared
to CD14+ monocytes (Figure 1, photo 1), which were larger
(averaging 15–18µm in diameter), ameboid in appearance, had
a lighter cytoplasm, and unilobar nucleus. This morphological
comparison confirms that CD56negCD16pos NK cells are visually
indistinguishable from other NK cell subsets and are clearly
not monocytes.
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Validating the Purity of Sorted NK Cell
Subsets
To check the purity of the sorted CD56dimCD16pos and
CD56negCD16pos NK cell subsets, we explored the normalized
expression values [transcripts per million (TPM)] of each
gene, to assess if any of the classical monocyte or neutrophil
gene signatures were detected on the bulk RNA-seq data
of the sorted cells. From this interrogation, we identified
one of the CD56negCD16pos NK samples as having higher
expression of classical monocyte genes (CD14 and CD33)
(Supplemental Figure 2), suggestive of trace monocyte
contamination. Thus, this sample was excluded from
further analysis leaving us with 7 CD56negCD16pos and 7
CD56dimCD16pos NK subsets for downstream differential
expression analysis. All remaining samples lacked expression
of CD14, CD33, and CD34 (Supplemental Figure 3A). In
addition, we found that neither NK cell subset expressed
neutrophil-associated genes, such as CD66b (CEACAM8),
ARG1, MPO, ABCA13, CA1, IFIT1B, CRISP3, LCN2, BPI,
CNTNAP3B, and PAD4 (Supplemental Figure 3B). However,
other neutrophil-associated genes, such as the integrin family
genes ITGAL (CD11a), ITGAM (CD11b), ITGAD (CD11d),
and ITGB2 (CD18) which are involved in innate immunity
(Roberts et al., 2016) and can be expressed by NK cells were
observed in both the CD56dimCD16pos and CD56negCD16pos
NK cell subsets (Supplemental Figure 3B). In addition, we
show that PTPRC (CD45) was highly expressed in both
the CD56negCD16pos and CD56dimCD16pos NK cell subsets
(logCPM = 11.37, Figure 2). CD45 is known to be expressed on
hematopoietic cells and more highly expressed on lymphoid cells
compared to myeloid cells based on BioGPS and MyGene.info
organizing online gene-centric information (Wu et al., 2013).
This criteria further supports the premise that CD56negCD16pos
cells are lymphocytes.
CD56negCD16pos and CD56dimCD16pos NK
Cells Transcriptome Expression Profiles
Using purified CD56dimCD16pos and CD56negCD16pos NK
cell subsets we compared their gene expression profiles and
identified 536 genes that were differentially expressed (p-
value<0.01 and FDR 0.05) among a combined total of 9,235
genes (Supplemental Figure 4, Supplemental Table 1). Of the
differentially expressed genes, 120 had a log Fold Change
(logFC) >1.5, with 73 genes downregulated and 47 genes
upregulated in CD56negCD16pos relative to CD56dimCD16pos
NK cells. Each sample showed appropriate expression based
on their flow sorting: CD56dimCD16pos vs. CD56negCD16pos
suggestingminimal cross-contamination. To further characterize
the CD56negCD16pos cell subset, we examined the expression
of genes that define and distinguish NK cells from other
cell types (Figures 2A,B, and Supplemental Table 1). Innate
Lymphoid Cells (ILCs) have been categorized into 5 Groups:
NK cells that differ based on developmental trajectories from
ILC of Group 1 (ILC1) yet both display type 1 immunity,
Group 2 (ILC2) able to produce type 2 cytokines, Group 3
(ILC3) defined by their capacity to produce IL-17A and IL-
22 and lymphoid tissue-inducer cells (LTi) involved in the
creation of secondary lymphoid organ (Vivier et al., 2018).
ILC2s are also defined by their expression of GATA3, BCL11B,
and GFI1 which we found to be expressed at similar levels
within CD56negCD16pos relative to the CD56dimCD16pos NK
cells (Figure 2C). However, amphiregulin (AREG) which is
expressed by ILC2 group, appeared slightly downregulated in
CD56negCD16pos relative to CD56dimCD16pos NK cells (logFC of
−1.32, p-value = 2.24E-06 and FDR of 0.0001). Regarding ILC3
genes, AHR was similarly expressed in both NK cell subsets but
neither CD56negCD16pos nor CD56dimCD16pos cells expressed
CSF2 and RORC, considered classical ILC3 genes. Together,
the transcriptional profile for CD56negCD16pos cells conform to
neither Group 2 nor 3.
CD56negCD16pos NK Cells Display a
Transcriptome Signature Reminiscent of
Adaptive NK Cells
Even though 98.7% of genes shared expression between the two
NK cell subsets, the differentially expressed genes shed light
on functional differences between these two cell populations.
Applying our NK-centric transcriptomic analysis, we show
that both CD56negCD16pos and CD56dimCD16pos NK cells
express activation and maturation markers such as KLRD1
(CD94), CD96, and B3GAT1 (CD57) (Figure 2B). However,
CD56negCD16pos NK cells had lower expression of CLEC2C
(CD69, logFC of −1.45, p-value = 3.96E-10 and FDR of 7.06E-
08) and CD38 (log CPM of 7.47 with logFC of −0.53, p-value =
0.0005 and FDR of 0.014) relative to CD56dimCD16pos NK cell. In
contrast, CD56negCD16pos NK cells tend to express more HLA-
DRA (logCPM of 5.78 with logFC of 0.91, p-value = 0.001 and
FDR of 0.03) and CD6 (logCPM of 6.32 with logFC of 0.96, p
= 4.84E-06 and FDR of 0.0002) relative to CD56dimCD16pos NK
cell. As expected, NCAM-1 (CD56) was strongly downregulated
in CD56negCD16pos cells compared to CD56dimCD16pos NK cells
(logFC of −5.84, p-value = 2.17E-198 and FDR of 2.03E-194).
Regarding their ability to proliferate, MKI67 (Ki67) was not
differentially expressed (logFC of 0.42, p-value = 0.18) between
the two subsets. Although, we observed higher expression of SPI1
(PU.1, logFC of 2.65, p-value= 0.0002 and FDR of 0.006) for the
CD56negCD16pos relative to CD56dimCD16pos NK cells. SPI1 has
been suggested to play a role in NK cell proliferation (Sun, 2016).
Besides potential cytotoxic and pro-inflammatory functions,
NK cells have been implicated in regulating immunity by killing
activated T cells or antigen-presenting cells (Ferlazzo et al.,
2002; Waggoner et al., 2011; Crouse et al., 2014). Therefore,
we queried the CD56negCD16pos NK cell transcriptome for
immunoregulatory cytotoxic activity. Interestingly, SELL
(CD62L, logFC of −3.08, p-value = 9.28E-17 and FDR of
1.09E-13) and ZBTB16 (PLZF, logFC of −2.52, p-value =
2.65E-14 and FDR of 1.24E-11) gene expression was significantly
lower in CD56negCD16pos relative to CD56dimCD16pos NK
cells, and both ITGAE (CD103) and ITGA1 (CD49a) were
not expressed which suggests that CD56negCD16pos cells
may be a form of adaptive NK cell. This is consistent with
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FIGURE 2 | Continued
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 April 2020 | Volume 10 | Article 162
Forconi et al. New Hope for CD56negCD16pos NK Cells
FIGURE 2 | Heatmap and MA plot of selected differentially expressed genes associated with NK cell function. (A) Heatmap of selected NK cell genes comparing
CD56negCD16pos and CD56dimCD16pos NK cells. The id between the brackets are the protein name for that particulate gene, i.e., gene symbol (protein name),
NCAM1 (CD56). (B) MA plot of differential expression analysis between CD56negCD16pos and CD56dimCD16pos NK cell subsets. The MA plot illustrates a log2 fold
change of NK specific gene expression in CD56negCD16pos relative to CD56dimCD16pos cells and the average normalized expression counts of genes expressed by
CD56negCD16pos cells. Protein names are used in the MA plot for ease of comparison to flow data even though these results are for gene expression. The Red dots
indicate genes that have significantly higher expression in CD56negCD16pos relative to CD56dimCD16pos NK cells (with BH-adjusted p-value < 0.01 and FDR < 0.05),
whereas blue dots indicate genes that have significantly lower expression (with BH-adjusted p-value < 0.01 and FDR < 0.05), and gray dots are genes that are
similarly expressed. (C) Boxplot of gene expression profiles that define Innate Lymphoid Cells (ILCs): AHR, AREG, BCL11B, CSF2, GATA3, GFI1, IRGAE, RORC
comparing CD56negCD16pos relative to CD56dimCD16pos NK cells.
Schlums et. al who characterized adaptive CD56dim NK cells
as CD62L−CD103−CD49a−PLZF1− (Schlums et al., 2015).
Moreover, FCER1G (FCεRγ) was strongly downregulated (logFC
of −1.39, p-value = 8.43E-09 and FDR of 1.05E-06, respectively)
and to a lesser extent lower levels of SH2D1B (EAT-2) (logFC of
−0.69, p-value = 4.55E-06, FDR of 0.0002) were observed for
CD56negCD16pos compared to CD56dimCD16pos NK cells. These
genes have been correlated with a loss of immunoregulatory
cytotoxic activity (Schlums et al., 2015) further supporting the
categorization of CD56negCD16pos NK cells as adaptive NK cells.
CD56negCD16pos NK Cells Express Higher
Levels of PDCD1 and LILR Family
Inhibitory Receptors Relative to
CD56dimCD16pos NK Cells
To evaluate the therapeutic potential of these two NK cell
subsets, we examined the expression of common NK cell
inhibitory molecules (Figure 2B). Most of the KIR members,
TIGIT and LAIR1 were similarly expressed by CD56negCD16pos
and CD56dimCD16pos cells. But interestingly, CD56negCD16pos
NK cells expressed significantly lower KLRG1 (logFC of
−1.48) and KLRB1 (CD161, logFC of −2.43) compared to the
CD56dimCD16pos NK cells, whereas KLRC1 (NKG2A, logFC
of −0.97) and HAVCR2 (TIM-3, −0.63) were only slightly
downregulated in CD56negCD16pos relative to CD56dimCD16pos
NK cells. In contrast, PDCD1 (PD-1, logFC of 2.26) and LILR
family members, LILRB1 (logFC of 1.21) and LILRB2 (logFC of
3.35) were observed to be upregulated within CD56negCD16pos
compared to CD56dimCD16pos NK cell. However, PDCD1 was
weakly expressed within CD56negCD16pos cells (logCPM of
4) compared to higher expression of LILRB1 (logCPM of 6).
Together these data suggest that CD56negCD16pos NK cells are
not exhausted but do overexpress distinct inhibitory receptors
that may pose a challenge to overcome with NK-based immune
checkpoint inhibitors.
CD56negCD16pos NK Cells Express Low
NKp80 & NKp46 but High CD16, CD32 and
Perforin Relative to CD56dimCD16pos NK
Cells
We previously showed that CD56negCD16pos NK cells were
poorly cytotoxic in K562 co-culture assays (Forconi et al.,
2018), however at the transcriptional level we observed
similar gene expression of some activation (KLRC2/NKG2C,
SLAMF7/CRACC, TRAIL, CRTAM/CRTAM), co-stimulation
(CD244/2B4, KLRK1/NKG2D) and natural cytotoxic receptors
(NCR3/NKp30) for these two subsets (Figure 2B). Yet,
CD56negCD16pos NK cells expressed less KLRF1 that codes
for the natural cytotoxic receptor NKp80 (logFC−3.14, p-value
= 6.02E-16 and FDR of 4.03E-13), NCR1 (NKp46, logFC −1.25,
p-value = 1.13E-09 and FDR of 1.63E-07), CD226 (DNAM-
1, logFC −1.55, p-value = 1.66E-11 and FDR of 4.39E-09)
and CD160 (logFC −1.11, p-value = 1.72E-08 and FDR of
1.87E-06) which might explain in part the loss of cytotoxicity
against K562 cells along with the absence of the CD56 adhesion
molecule. In contrast, FCGR3A (CD16a) is highly expressed
on both CD56negCD16pos NK cells (logCPM of 9.81) and
CD56dimCD16pos NK cells. CD56negCD16pos NK cells expressed
higher levels of FCGR3B (CD16b) (logFC of 2.03, p-value
= 0.0005 and FDR of 0.013), FCGR2A (CD32A, logFC of 1.4,
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p-value= 3.69E-10 and FDR of 6.78E-08), and FCGR2B (CD32B,
logFC of 1.06, p-value = 7.68E-07 and FDR of 5.25E-05) relative
to CD56dimCD16pos NK cells with a slightly elevated expression
of CD84 (logCPM of 6.47, logFC of 0.76, p-value = 4.07E-05
and FDR of 0.001), respectively. We were surprised to see
significantly elevated expression of cytotoxic molecules such
as MPEG1 (perforin 2) for the CD56negCD16pos compared to
CD56dimCD16pos NK cells (logFC of 3.55, p-value = 1.44E-07
and FDR of 1.25E-05). Despite this interesting observation, other
genes involved in direct cytotoxicity, such as LYZ (lysozyme),
LAMP-1 (CD107a), FASLG (FAS-L), GZMH and GZMM
(granzyme H and M) were not differentially expressed between
the CD56negCD16pos and CD56dimCD16pos NK cells, supporting
their ability to kill target cells by degranulation and through the
FAS-L/FAS pathway. CD56negCD16pos NK cells expressed PRF1
(perforin 1, logCPM of 10.54, logFC of−0.62),GZMA (granzyme
A, logCPM of 8.06, logFC of −0.75) and GZMB (granzyme B,
logCPM of 9.15, logFC of −0.8) these markers were slightly
lower for CD56negCD16pos compared to CD56dimCD16pos NK
cells. Another gene related to cytotoxicity GNLY (granulysin
or LAG2) was significantly downregulated in CD56negCD16pos
relative to CD56dimCD16pos NK cells (logCPM of 9.83 and logFC
of −2.27). Overall, these data suggest that CD56negCD16pos NK
cells retain cytotoxic potential, albeit mediated through different
mechanisms compared to CD56dimCD16pos NK cells.
CD56negCD16pos NK Cells Express Less
IL-2, IL-12, and IL-18 Receptors Relative to
CD56dimCD16pos NK Cells
As shown in Figure 2B, we found no differences in IL2RG gene
expression (subunit γ of the IL2 receptor), IL15RA (receptor
for IL15), IL12Rb1 (subunit β 1 of the IL12 receptor) between
these two NK cell subsets, whereas the other chain of the IL12
receptor (IL12Rb2, logFC of −2.4, p-value = 7.95E-17 and
FDR of 1.06E-13) was found to be significantly downregulated
in CD56negCD16pos relative to CD56dimCD16pos NK cells.
Significant differences were also observed for IFNGR1 (logFC
of −1.48, p-value = 2.41E-14 and FDR of 1.19E-11), and both
IL18R1 (IL18 receptor, logFC of −3.73, p-value = 4.65E-16 and
FDR of 3.35E-13) and IL18RAP (IL18 receptor accessory protein,
logFC of−3.7, p-value= 2E-23 and FDR of 6.25E-20). However,
IL18BP which encodes the IL18 binding protein is similarly
expressed in both CD56negCD16pos and CD56dimCD16pos NK
cells (logFC of 0.007). Interestingly, CD122 (IL2RB/IL15RB)
appeared to be slightly downregulated in CD56negCD16pos
relative to CD56dimCD16pos NK cells (logFC of −0.66, p-value
= 4.85E-05 and FDR of 0.001). These observations suggest that
CD56negCD16pos may be impervious to activation by IL2, IL12,
IL15, and IL18 cytokines.
CD56negCD16pos Cells Do Not Differ From
CD56dimCD16pos NK Cells in Cytokine
Gene Expression
We assessed the cytokine expression for CD56negCD16pos and
CD56dimCD16pos NK cells without any in vitro pre-stimulation
(Figure 2B). We did not observe any differences in basal
expression levels for IL10, IL15, IL16, IL32, or IFNγ between the
two NK subsets. However, we observed that both NK cell subsets
expressed high TGFβ levels (logCPM of 10.38) which suggests an
inherent anti-inflammatory role.
Validation of Gene Expression by Flow
Cytometry
Most of the genes differentially expressed when comparing
CD56negCD16pos to CD56dimCD16pos NK cells that are
highlighted in the RNA-sequencing experiment have already
been described at the protein expression level in previous studies
(Forconi et al., 2018; Voigt et al., 2018). CD56dimCD16pos
compared to CD56negCD16pos NK cells express less NKp80,
IL18Ra, CD161, NKp46, DNAM1 with no differences for CD57,
Perforin 1, CD11c, NKG2D, NKG2C and most of the KIRs.
We performed additional flow cytometry experiments and
confirmed that CD56dimCD16pos and CD56negCD16pos NK
cells cluster separately (Figure 3A). We also confirmed higher
expression of IL18Ra, CD62L, DNAM1, and TIM-3 on the
CD56dimCD16pos compared to CD56negCD16pos NK cells and
higher expression of CD32 and PD-1 on the CD56negCD16pos
compared to CD56dimCD16pos NK cells (Figure 4B) but no
difference in granzyme B expression, thereby validating our
RNAseq results.
Biological Processes Enriched Using
gProfiler
Because of the low number of genes differentially expressed
between CD56negCD16pos and CD56dimCD16pos NK cells, no
gene set enrichment was suitable within the GSEA software.
However, using the free online tool gProfiler (Figure 4), we
were able to visualize which biological processes were enriched
using the 536 significantly differentially expressed genes. The
Manhattan plot shows the most significant biological processes
involved are immune system processes, leukocyte activation, cell
activation, and immune response. These results are consistent
with our previous observations that CD56negCD16pos NK cells
are activated and should be able to drive cytotoxic responses
although through alternative pathways to those commonly used
by other NK cell subsets.
DISCUSSION
In this study, we have shown that CD56negCD16pos NK
cells share morphological and transcriptional profiles
with CD56dimCD16pos NK cells. In fact, CD56negCD16pos
cells expressed multiple NK cell markers including KIRs,
NKG2C, NKp30, CD16a, NKG2D, 2B4, CD57, TRAIL,
CRTAM and CRACC. Moreover, our previous study
highlighted the phenotypic similarities between these two
NK cell subsets (Forconi et al., 2018) which was supported
by the Voigt et.al proteomic study (Voigt et al., 2018).
Together, these findings confirm that CD56negCD16pos
cells are true NK cells. However, we find interesting
differences between these two NK cell subsets that might
impact functional differences and potential targets that
may be potentially harnessed therapeutically to drive NK
cell-mediated cytotoxicity.
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FIGURE 3 | Validation of RNA-sequencing data by flow cytometry. (A) Heatmap of markers expressed on both CD56dimCD16pos (in green) and CD56negCD16pos (in
purple) NK cells from eBL (in turquoise) and healthy (in pink) children. (B) Violin plots showing the protein expression of IL18Ra, CD62L, DNAM1, TIM3, CD32,
granzyme B and PD-1 from both CD56dimCD16pos (in green) and CD56negCD16pos (in purple) NK cells. *Represents a p-value < 0.05.
First, we showed that CD56negCD16pos cells expressed a
unique inhibitory marker profile with higher LILR family
and PDCD1 gene expression. LILRB1 encodes for LILRB1
transmembrane receptors which contain 4 ITIMs motif in the
cytoplasmic tail and is expressed by various immune cells (Zhang
et al., 2015). After stimulation by its ligands, various HLA class
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FIGURE 4 | Manhattan plot of functional profiling of the list of upregulated genes from CD56negCD16pos relative to CD56dimCD16pos cells. Using the online tool
gProfiler and the ordered g:GOSt query, we assessed which biological process (BP) will be linked to the list of 536 significantly differentially expressed genes from
CD56negCD16pos relative to CD56dimCD16pos cells. The x-axis represents functional terms that are grouped and color-coded by data sources [molecular function (MF),
biological process (BP), cell component (CC)]. The y-axis shows the adjusted enrichment p-values in negative log10 scale. Adjusted p-values g:GOSt used Bonferroni
correction and a threshold of 0.01. On the table, adjusted p-values were color coded as yellow for insignificant findings to dark blue with highest significance.
I molecules among others, trigger a strong inhibition signal in
order to limit inflammatory and cytotoxic responses. Its most
efficient ligand is a dimerized HLA-G which was described
as up-regulated in some human tumors such as breast cancer
(Lefebvre et al., 2002), certain AML (acute myeloid leukemia)
(Kang et al., 2015) and cutaneous T cell lymphoma (Urosevic
et al., 2004) in which both CD8+ T and CD56+ NKT cells highly
expressed LILRB1 and thereby possibly contributed to tumor
immune escape. More recently, LILRB1 blockade was shown to
enhance cytotoxic CD8+ T cell activity using bispecific T cell
engager (BiTE) (Kim et al., 2019) molecules, highlighting the
potential of the LILRB1 receptor as an anti-cancer therapeutic
target. LILRs are not known to be included in a T cell exhaustion
signature (McLane et al., 2019), contrary to other markers such
as PD-1, TIM-3, TIGIT, LAG3, CTLA-4, KLRG1, BTLA, CD160,
and 2B4. In our study, PDCD1, coding for the PD-1 protein,
was more highly expressed for CD56negCD16pos relative to
CD56dimCD16pos NK cells even though its expression was very
low compared to most other genes of interest (Figure 2B). At
the proteome level, PD-1 was not differentially expressed across
NK cell subsets (Voigt et al., 2018). PD-1 is a popular target for
immune checkpoint inhibitors, although insufficient in isolation
to determine the extent it plays in T cell exhaustion (Blank
et al., 2019; McLane et al., 2019). In this viewpoint article, the
authors suggested the potential for adaptation of T cells into an
exhaustion profile in order to limit immunopathology during
chronic infections (Blank et al., 2019). Similarly, we suggest that
CD56negCD16pos NK cells are an adaptation of CD56dimCD16pos
NK cells under conditions of chronic infections or persistent
tumor ligand stimulation. In our study of eBL patients, we
observed that KLRG1, TIM-3 and CD160 had lower expression
in CD56negCD16pos relative to CD56dimCD16pos NK cells.
Moreover, CTLA-4 and BTLA were not expressed at all, which
suggests that the CD56negCD16pos NK subset does not appear to
have a more exhausted profile than the other NK cells subsets
but they clearly express multiple inhibitory markers which could
limit immune responses.
As NK cells function depend on multiple signals triggered by
both inhibitory and activation receptors, we assess as well which
activation and cytotoxic markers were strongly differentially
expressed between CD56dimCD16pos and CD56negCD16pos NK
cells. Despite numerous markers similarly expressed (CD6, HLA-
DR, CD57, CD84, TRAIL, NKp30, NKG2C, NKG2D, 2B4...),
CD56negCD16pos NK cells showed a strong downregulation of
KLRF1 coding for the cytotoxic receptor NKp80 and to a lesser
extent NCR1 coding for NKp46 relative to CD56dimCD16pos
NK cells. A recent study described NKp80 as a marker of NK
cell maturity (Freud et al., 2016). In brief, they characterized
NKp80neg NK cells from secondary lymphoid tissues as stage
4a of NK cell development, which also included low expression
of perforin, T-bet, EOMES, lack of Granzymes A, B and K but
higher expression of RORC2 and AHR (features shared with
ILC3). Despite the expression of AHR in both CD56dimCD16pos
and CD56negCD16pos NK cell subsets, RORC2 was absent and
we didn’t observe a significant differential expression of T-
bet and EOMES genes. However, Perforin 1, granzyme A
and B genes appeared to be slightly downregulated within
the CD56negCD16pos NK cells. Regarding NKp46, we have
previously shown that the expression of this cytotoxic receptor
is significantly lower for children exposed to Plasmodium
falciparum (Forconi et al., 2018). These data suggest another role
for NKp80 and potentially an adaptation of NKp46 expression
within eBL children within the context of malaria, EBV co-
infections and the eBL pathogenesis. Despite the less expression
of cytotoxic receptors essential in natural direct cytotoxicity, NK
cells have other ways to kill target cells involving the presence
of IgG antibodies. Interestingly, we observed upregulation
of low-affinity Fcγ receptor CD16, the medium-affinity Fcγ
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FIGURE 5 | Hypothetical model of CD56dimCD16pos and CD56negCD16pos NK cells cytotoxic pathways against both Plasmodium falciparum-infected red blood cells
(Pf-iRBC) and endemic Burkitt lymphoma (eBL) tumor cells. (A) Proposed killing pathways used by CD56dimCD16pos NK cells against iRBCs and eBL tumors primarily
(Continued)
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FIGURE 5 | mediated by natural direct cytotoxicity (direct killing) through the activation of cytotoxic receptors (NKp46, NKp30, NKp80, NKG2D…) but also antibody
dependent cell cytotoxicity (ADCC) through CD16a activation. (B) Proposed killing pathways used by CD56negCD16pos NK cells against iRBC and eBL tumors. Due to
the low expression of cytotoxic receptors, direct killing appears to be incapacitated however other killing pathways based on recognition of opsonized targets might
be enhanced.
receptor CD32 and Perforin 2 genes within the CD56negCD16pos
compared to the CD56dimCD16pos NK cell subset. There are
two genes which encode the CD16 protein: FCGR3A and
FCGR3B and they share more than 95% of homology so that
common CD16 flow cytometry antibodies cannot distinguish
them from one another (Ravetch and Perussia, 1989). However,
the expression of these two genes were described as cells-
specific and with different functions from CD16b which is
a glycophosphatidylinositol (GPI) -anchored molecule without
intracellular signaling motifs. In order to measure cells specificity
of both CD16a and CD16b, Ravetch’s team reconstituted these
receptors in transgenic mice (Li et al., 1996). They showed
that CD16a is expressed by macrophages and NK cells whereas
CD16b is exclusively expressed by neutrophils. In our study
we show that CD16a is highly and similarly expressed by
CD56dimCD16pos and CD56negCD16pos NK cells, however,
CD16b is significantly upregulated within CD56negCD16pos NK
cell subset. CD16a or FCGR3A receptor is known as an important
mediator of antibody dependent cell cytotoxicity (ADCC), an
indirect mechanism used by NK cells and other innate immune
cells to kill tumors and infected host cells (Hart et al., 2017; Arora
et al., 2018; Victor et al., 2018). CD16b has been implicated as
an essential mediator of antibody-dependent respiratory burst
(ADRB) by neutrophils and has also been shown to be essential
for immune complexes (ICs) but not necessarily involved in
phagocytosis (Fossati et al., 2002). A recent study showed that
CD16b can also regulate ADCC by neutrophils in competition
with CD16a (Treffers et al., 2018), and in fact low copy number
variation (CNV) of the gene FCG3RBwithin activated cells might
increase ADCC capacity. Our transcriptome analysis was not
able to assess CNV although we observed a logCPM of 5.03
for CD16b which is twice less than logCPM of 9.81 for CD16a.
It will be important to consider CNV in future experiments in
order to clearly determine the role of CD16b within NK cells.
Both FCGR2A (CD32a) and FCGR2B (CD32b) were also more
highly expressed by CD56negCD16pos than CD56dimCD16pos
NK cells. These findings suggest that CD56negCD16pos NK cells
may be superior in recognizing antibody opsonized targets.
Using recognition of the complement, CD11b and CD18 were
found expressed within NK cells from our study population.
The heterodimer CD11b/CD18 is called complement receptor 3
(CR3, Mac1 or αMβ2). CR3 is a multi-functional receptor which
was described as predominantly expressed on myeloid and NK
cells (Ross and Vetvicka, 1993; Vorup-Jensen and Jensen, 2018)
and involved in NK cell cytotoxicity (Lee et al., 2017). CR3 can
interact with Fc receptors for adhesion to immune complexes and
therefore enhance cell mediated antibody-dependent cytotoxicity
(Ortiz-Stern and Rosales, 2003).
Cytokines also play an essential role in NK cell activation
and function. In this study we observed a strong significant
downregulation of IL18 receptor (IL18RAP and IL18R1) as well
as IL12RB2, β chain of IL12 receptor within CD56negCD16pos
relative to CD56dimCD16pos NK cells. IL18 and IL12 are both
known to be crucial in NK cell activation, therefore, the
downregulation of these receptors on CD56negCD16pos NK cells
might impair their activation. However, it was previously shown
that both IL18 and IL12 receptors are silenced in adaptive
CD56dim NK cells in order to block their ability to produce
immunoregulatory cytokines (Schlums et al., 2015), whereas the
IL15 receptor (IL15RA) is still expressed. We also show that
CD56negCD16pos NK cells are CD62L−CD103−CD49a−PLZF1−
with a downregulation of FCER1G (FCεRγ) and SH2D1B
(EAT-2). This phenotype has been correlated with a loss of
immunoregulatory cytotoxic activity (Schlums et al., 2015).
Similar observations were made for HIV-positive individuals
who had broadly reactive neutralizing antibodies (bnAbs),
lower expression of IL12 and IL18 receptors and PLZF1
yet with higher expression of CD6 (Bradley et al., 2018),
confirming an adaptive-like NK cell phenotype. In addition,
HIV-positive individuals with bnABs had a higher proportion
of CD56negCD16pos NK, which was associated with better
viral control. Interestingly, a positive correlation was observed
between CD56negCD16pos NK cells and mRNA expression of
RAB11F1P5, encoding for Rab11 recycling endosome molecule,
which was also found to be increased in CD56negCD16pos
NK cells from children in our study. Together, these studies
support the development of adaptive CD56negCD16pos NK cells
as adaptation to chronic infections.
In summary, we present a hypothetical model (Figure 5)
contrasting killing pathways used by CD56dimCD16pos and
CD56negCD16pos NK cells against eBL tumor cells as well as
P. falciparum-infected red blood cells (iRBC). P. falciparum
has been consistently linked to eBL pathogenesis (Moormann
and Bailey, 2016). Here, we hypothesize that continual malaria
infections induce NK cell adaptation thereby increasing
the prevalence of CD56negCD16pos NK cells. Figure 5A
illustrates how CD56dimCD16pos NK cells kill iRBC after direct
recognition between NKp46 and its putative ligand, P. falciparum
erythrocyte membrane protein 1 (PfEMP-1) (Wolf et al., 2017).
CD56dimCD16pos NK cells also use direct recognition to kill
tumor cells by activation of multiple receptors. However, KIRs,
NKG2A/CD94 and 2B4 can trigger tolerance and therefore allow
immune escape of the tumor cells. Determining which NK cell
inhibitory ligands are expressed by tumors is an area of ongoing
investigation. Finally, in the presence of antibodies directed
against iRBCs and tumor cells neo-antigens, CD56dimCD16pos
NK cells can kill both tumor cells and iRBCs through ADCC
triggered by CD16a. ADCC against iRBCs has already been
well-described by others (Hart et al., 2017; Arora et al., 2018).
In contrast, we hypothesize that the main method of killing
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for CD56negCD16pos NK cells is through antibody dependent
cytotoxicity (Figure 5B). Expression of all CD18/CD11a/b/c as
well as CD16a, CD16b, CD32a, CD32b and Perforin 2 suggests a
multifaceted involvement of antibody opsonization in the killing
capacity of CD56negCD16pos NK cells. P. falciparum induces a
broad range of antibodies directed against the many parasite
antigens that are able to trigger ADCC and ADRB (Moormann
et al., 2019). Another important component for killing target cells
is complement. Present in plasma, iC3b can be fixed on iRBCs
as well as tumor cells and thereby opsonize the target for innate
cells. This immune complex can be recognized by CR3 expressed
on NK cells and trigger complement dependent cell-mediated
cytotoxicity (CDCC) against the target cells. Moreover, it was
shown that CR3 should be able to communicate with the Fcγ
receptors (CD16a/b) and therefore be able to enhance ADCC
and ADRB functions (Lee et al., 2017). We therefore suspect
that ADCC can as well be important against tumor cells if the
tumor is expressing surface antigens for antibody opsonization.
In contrast, we and others have shown that CD56negCD16pos
NK cells are not well-adapted for natural direct cytotoxicity
because of their strong downregulation of multiple cytotoxic and
activation receptors. Thus, CD56negCD16pos NK cell abundance
appears to be a refined adaptation influenced by chronic diseases,
that focuses NK cell mediated cytotoxicity toward antibody
opsonized targets.
As a limitation of our study, bulk RNA-sequencing didn’t
allow us to assess the copy number variation (CNV) that can
impact the role of CD16b on ADCC. CD56negCD16pos NK cells
might use othermeans to kill target cells such as ADRB or CDCC.
These pathways will need to be assessed in functional assay in
order to determine which cytotoxic mechanisms are engaged by
CD56negCD16pos NK cells.
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Supplemental Table 1 | Genes significantly differentially expressed between the
CD56negCD16pos NK cells and CD56dimCD16pos NK cells (Benjamini-Hochberg
procedure (BH) adjusted p-value < 0.01 and false discovery rate (FDR) < 0.05).
Supplemental Figure 1 | CD56negCD16pos NK cells across population. (A)
Representative cytoplots of NK cell subsets repartition from PBMCs within healthy
American and Kenyan adults as well as healthy and eBL Kenyan children.
CD56pos NK cells are gated in red box and CD56neg in blue box. (B) Percentage
of CD56negCD16pos NK cells across our different groups: healthy American,
healthy Kenyan, healthy children from Nandi (EBV+/Pf-), healthy children from
Kisumu (EBV+/Pf+) and eBL children (EBV+/Pf+). ∗∗∗∗Represents a p-value <
0.0001; ∗∗∗represents a p-value < 0.001; ∗∗represents a p-value < 0.01.
∗Represents a p-value < 0.05.
Supplemental Figure 2 | Excluding NK subsets with possible monocyte
contamination. Boxplot showing the expression of monocyte associated genes
(CD14, CD33, and CD34). We identified one of the sorted CD56dimCD16pos NK
cells (highlighted red in the boxplot), to have elevated expression of monocyte
marker genes (CD14 and CD33). Elevated expression of these 2 genes could
have been due to monocyte contamination during the sorting process of that
particular sample. This sample was excluded from all downstream analysis.
Supplemental Figure 3 | Purity of flow sorted CD56negCD16pos and
CD56dimCD16pos cell subsets. (A) Boxplot of monocyte gene expression profile
CD14, CD33, and CD34 genes expression within both CD56negCD16pos and
CD56dimCD16pos NK cells. (B) Boxplot of neutrophil gene expression profile
ARG1, ARHGEF12, BPI, CA1, CEACAM8, CNTNAP3B, CRISP3, FUT4, IFIT1B,
ITGAM, ITGB2, LCN2, and MPO genes expression within both CD56negCD16pos
and CD56dimCD16pos NK cells. ∗∗∗Represents a p-value < 0.00001; ∗represents a
p-value < 0.01.
Supplemental Figure 4 | Heatmap of all differentially expressed genes for
CD56negCD16pos compared to CD56dimCD16pos NK cells. Differential gene
expression analysis identified 536 genes to be significantly differentially expressed
(Benjamini-Hochberg method [BH] adjusted p-value < 0.01 and False Discovery
Rate (FDR) < 0.05) between the CD56negCD16pos and the CD56dimCD16pos NK
cell subsets. The heatmap shows hierarchical clustering based on the expression
profile of the 536 differentially expressed genes between the two NK cell subsets.
The color key indicates the intensity associated with normalized expression
values. Of the 536 genes identified to be differentially expressed between these
two NK cell subsets, 350 genes were downregulated among the
CD56negCD16pos cells compared to the CD56dimCD16pos and 186 genes were
upregulated in the CD56negCD16pos cells compared to the CD56dimCD16pos cells
(Supplemental Table 1).
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